Skip to main content
Caplight Logo









Selecxine

Selecxine

Private
PohangHealthcare & Life Scienceshttps://selecxine.com/

Last Round

Series B

Mar 22, 2022

Total Funding Raised

$49.75M

Company Overview

Selecxine is a biopharmaceutical company that develops anti-cancer immunotherapeutics using its proprietary antibody discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyantibody-cytokine conjugateantibody discoverybiopharmacancer immunotherapydrug discoveryphage displayepitope mappingcell-based screeningprecision medicinebiotechclinical-stage biotechantibody engineeringCDMOcontract development and manufacturing organization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Selecxine Comparables

Compare Selecxine with similar companies based on industry and business-model similarity.

Selecxine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asher Biotherapeutics
84%
Synthekine
82%
Anaveon
81%

Selecxine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 22, 2022
Series AMay 7, 2020

Key People

Founding team and executive leadership

GilTae Wie

COO CFO

Executive Team

Selecxine Investors

Notable investors and investment history

Selecxine investors
InvestorRounds
Hanwha Investment & SecuritiesSeries A, Series B
iM Investment PartnersSeries B
KCLAVIS InvestmentSeries B
UTC InvestmentSeries B
Medici InvestmentSeries B
K-Run VenturesSeries A
Stonebridge VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 29, 2022

    $27M round led by Hanwha Investment & Securities and Medytox Venture Investment.

  • May 7, 2020

    $11M round with participation from Hanwha Investment & Securities.

Selecxine Filings

Explore SEC and related filing metadata, where available.

Selecxine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Selecxine's valuation, stock price, and market status.

Is Selecxine a public or private company?

Selecxine is a private company.

What is the current stock price of Selecxine?

Selecxine is a private company with no public stock price. No recent secondary market data is available.

How much is Selecxine worth (valuation)?

Valuation information for Selecxine is not publicly available.

Can I buy Selecxine stock?

Selecxine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Selecxine's last funding round?

Selecxine's most recent funding round was Series B on March 29, 2022.

Who are the main investors in Selecxine?

Key investors in Selecxine include Hanwha Investment & Securities, Stonebridge Ventures, Medytox Venture Investment, SJ Investment Partners, STIC Ventures.

Will Selecxine IPO soon?

No public IPO plans have been announced for Selecxine.

How can I track Selecxine secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Selecxine's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPohang
Employee Range9
Year Founded2018
Last FundingMar 22, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?